Stay updated on Clinical Trial HER2+ Breast Cancer: Chemo-free PET Strategy

Sign up to get notified when there's something new on the Clinical Trial HER2+ Breast Cancer: Chemo-free PET Strategy page.
Latest website image capture
Clouds background image

Latest updates to the Clinical Trial HER2+ Breast Cancer: Chemo-free PET Strategy page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a significant update in the study assessing the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab on HER2-positive breast cancer, focusing on predictive value for pathologic complete response and 3-year invasive disease-free survival.
    Difference
    0.1%
    Check dated 2024-06-06T14:44:49.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as informed consent, age, health status, and specific medical conditions. This change provides more comprehensive information for researchers and potential participants about who can join the study.
    Difference
    30%
    Check dated 2024-05-22T21:37:01.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:18:13.000Z thumbnail image

Stay in the know with updates to Clinical Trial HER2+ Breast Cancer: Chemo-free PET Strategy

Enter your email address, and we'll notify you when there's something new on the Clinical Trial HER2+ Breast Cancer: Chemo-free PET Strategy page.